Elan Pharmaceuticals
As of the edition of 20 October 2026, Elan Pharmaceuticals runs 5 drugs, 4 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Stopped | 1 |
| Total | 5 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Verapamil | none listed | 8 |
| Tizanidine | none listed | 3 |
| Ziconotide | none listed | 1 |
| Ziconotide acetate | none listed | 1 |
A route B row is one company at one target.
Where its trials are
- Immune system: 2 trials led
- Nervous system: 2 trials led